MiNK Therapeutics stockholders elect Garo Armen and Barbara Ryan as Class II directors, ratify KPMG as auditor

MiNK Therapeutics, Inc.

Garo Armen received 29,157,446 for and 282,326 withheld; Barbara Ryan 29,193,530 for and 246,242 withheld.
KPMG LLP ratified as independent auditor for FY2023 with 30,644,494 for, 5,764 against, 110,413 abstentions.
Quorum of 30,760,671 shares (89.6% of outstanding) present at June 13, 2023 Annual Meeting.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

MiNK Therapeutics, Inc. shareholders approved Election of Garo Armen and Barbara Ryan as Class II directors at the 2023-06-13 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-13

Exact text from the filing

Class II Director Nominees For Against Withheld Broker Non-Votes Garo Armen 29,157,446 0 282,326 1,320,899 Barbara Ryan 29,193,530 0 246,242 1,320,899

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

MiNK Therapeutics, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-13 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-13

Exact text from the filing

The votes cast at the Annual Meeting were as follows: For Against Withheld Broker Non-Votes 30,644,494 5,764 110,413 NA

View on SEC.gov

Browse all shareholder votes →

MiNK Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-028900

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.